Source-grounded facts extracted from Coherus Oncology, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Lee N. Newcomer was appointed as Director at Coherus Oncology, Inc..
“On February 2, 2022, upon the recommendation of its Nominating and Corporate Governance Committee (the “Nominating Committee”), the Board of Directors (the “Board”) of Coherus BioSciences, Inc. (the “Company”) increased the size of the Board from six directors to seven directors and appointed Dr. Lee N. Newcomer to fill the vacancy created by such increase.”
Vincent Anicetti resigned as Chief Operating Officer at Coherus Oncology, Inc..
“On December 1, 2021, Vincent Anicetti resigned from his role as Chief Operating Officer of Coherus BioSciences, Inc. (the “Company”), effective December 31, 2021 as part of a long-term succession plan.”
Alan C. Mendelson departed as Director at Coherus Oncology, Inc..
“deeply regrets to announce that Alan C. Mendelson, a member of the Company’s Board of Directors, unexpectedly passed away on Friday, October 8, 2021.”
Samuel Nussbaum departed as Member of the Board of Directors at Coherus Oncology, Inc..
“Samuel Nussbaum, M.D., a member of the Company’s Board of Directors, passed away on Thursday, September 23, 2021.”
Mary T. Szela resigned as Director at Coherus Oncology, Inc..
“On August 5, 2021, Mary T. Szela resigned from the Board of Directors (the “Board”) of Coherus BioSciences, Inc. (the “Company”), effective immediately upon notice of her resignation.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.